[Effect of Intestinal Cytochrome P450 3A on Phytochemical Presystemic Metabolism]

Overview

Journal Chin J Integr Med

Date 2005 Sep 27

PMID 16181542

Citations 1

Authors

Fang Xia

Xiao-Yin Chen

Affiliations

Soon will be listed here.

Abstract

Phytochemicals, orally administered substances, are found to undergo presystemic metabolism mainly in the intestine. Although early researches confirmed the role of intestinal bacteria in phytochemical presystemic metabolism, along with the development of molecular biology in investigating intestinal metabolism, a breakthrough has been won in research into metabolizing enzymes and transporters in intestine, which demands more attention and further studies. Recently, Cytochrome P450 3A has been found to be the most effective enzyme in mediating both oxidative (PhaseI) and conjugative (PhaseII) metabolism in the intestine. The present review summarizes the current findings correlated with the effect of intestinal cytochrome P450 3A on phytochemical presystemic metabolism, which provides a good basis for further research on phytochemical pharmacokinetics.

Citing Articles

A High-Performance Liquid Chromatography with Photodiode Array Detection Method for Simultaneous Determination of Three Compounds Isolated from : Assessment of the Effects on Cytochrome P450-Mediated Metabolism In Vitro and In Vivo.

Keem M, Seo S, Kim T, Jo B, Kim S, Yoon I Nutrients. 2023; 15(18).

PMID: 37764844 PMC: 10534693. DOI: 10.3390/nu15184061.

References

Lundahl J, Regardh C, Edgar B, Johnsson G . Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol. 1997; 52(2):139-45. DOI: 10.1007/s002280050263. View

Walter-Sack I, Klotz U . Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet. 1996; 31(1):47-64. DOI: 10.2165/00003088-199631010-00004. View

Kolars J, Lown K, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton S . CYP3A gene expression in human gut epithelium. Pharmacogenetics. 1994; 4(5):247-59. DOI: 10.1097/00008571-199410000-00003. View

Guengerich F . Cytochrome P450 enzymes in the generation of commercial products. Nat Rev Drug Discov. 2002; 1(5):359-66. DOI: 10.1038/nrd792. View

Wang Z, Kurosaki Y, Nakayama T, Kimura T . Mechanism of gastrointestinal absorption of glycyrrhizin in rats. Biol Pharm Bull. 1994; 17(10):1399-403. DOI: 10.1248/bpb.17.1399. View

Kupferschmidt H, Ha H, ZIEGLER W, Meier P, Krahenbuhl S . Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995; 58(1):20-8. DOI: 10.1016/0009-9236(95)90068-3. View

Ambudkar S, Dey S, Hrycyna C, Ramachandra M, Pastan I, Gottesman M . Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999; 39:361-98. DOI: 10.1146/annurev.pharmtox.39.1.361. View

Wacher V, Wu C, Benet L . Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995; 13(3):129-34. DOI: 10.1002/mc.2940130302. View

Paine M, Shen D, Kunze K, Perkins J, Marsh C, McVicar J . First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996; 60(1):14-24. DOI: 10.1016/S0009-9236(96)90162-9. View

10.

Cummins C, Salphati L, Reid M, Benet L . In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther. 2003; 305(1):306-14. DOI: 10.1124/jpet.102.044719. View

11.

Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich F . Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994; 270(1):414-23. View

12.

Nelson D . Cytochrome P450 and the individuality of species. Arch Biochem Biophys. 1999; 369(1):1-10. DOI: 10.1006/abbi.1999.1352. View

13.

Chan W, Nguyen L, Miller V, Harris R . Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci. 1998; 62(10):PL135-42. DOI: 10.1016/s0024-3205(98)00013-7. View

14.

Domanski T, Finta C, Halpert J, Zaphiropoulos P . cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001; 59(2):386-92. DOI: 10.1124/mol.59.2.386. View

15.

Omura T . Forty years of cytochrome P450. Biochem Biophys Res Commun. 1999; 266(3):690-8. DOI: 10.1006/bbrc.1999.1887. View

16.

Kolars J, Awni W, Merion R, Watkins P . First-pass metabolism of cyclosporin by the gut. Lancet. 1991; 338(8781):1488-90. DOI: 10.1016/0140-6736(91)92302-i. View

17.

Paine M, Khalighi M, Fisher J, Shen D, Kunze K, Marsh C . Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1998; 283(3):1552-62. View

18.

Wacher V, Silverman J, Zhang Y, Benet L . Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998; 87(11):1322-30. DOI: 10.1021/js980082d. View

19.

Honkakoski P, Negishi M . Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J. 2000; 347(Pt 2):321-37. PMC: 1220963. DOI: 10.1042/0264-6021:3470321. View

20.

Lewis D, Eddershaw P, Goldfarb P, Tarbit M . Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica. 1996; 26(10):1067-86. DOI: 10.3109/00498259609167423. View